bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital
June 2, 2025
Biotechnology
-
-
Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics
May 30, 2025
-
Sequire Spotlight Presents: Biolargo (BLGO) – 45% Revenue Growth & PFAS Tech Driving Market Impact
May 22, 2025
-
Sequire Spotlight: Birchtech Corp (BCHT) – Revolutionizing Forever Chemicals Removal in Water
May 22, 2025
-
Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15
May 21, 2025
-
Rani Therapeutics Announces Research Agreement with Chugai
May 19, 2025
-
BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS
May 19, 2025
-
Ocugen Provides Business Update with First Quarter 2025 Financial Results
May 9, 2025
-
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital
May 7, 2025
-
OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040
May 7, 2025
-
Pacaso — The $1.3 Trillion Secret That Everyday Investors Are Finally Invited To
May 6, 2025
-
NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update
April 24, 2025
-
Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003
April 23, 2025
-
OS Therapies FDA Meeting Request Granted
April 22, 2025
-
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs
April 21, 2025
-
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board
April 16, 2025